Immunocore
IMCR
29.41
-0.14
-0.47%
Immunocore
US · IMCR
#2968 by market cap
Listed 2021
29.41
-0.14
-0.47%
Live - 5344 symbols - heartbeat 59s ago
· 2026-10-07 19:54
After-hours
29.41
0.00%
- Market cap
- 1.51B
- P/E (TTM)i
- -79.49
- P/Bi
- 3.61
- EPSi
- -0.71
- Div yieldi
- 0.00%
- 52W posi
- 14%
Reader sentiment
Are you bullish or bearish on IMCR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.31, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +28.95% YoY
Margins
- Gross margin
- 98.73%
- Operating margin
- -11.34%
- Net margin
- -8.88%
Key ratios & quality
- Enterprise valuei
- 1.05B
- Altman Z-Scorei
- 1.31
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 30.01M | 33.66M | 41.04M | 36.48M | 174.36M | 249.43M | 310.20M | 400.02M |
| Gross profit | -- | -- | 41.04M | 36.48M | 173.27M | 248.39M | 307.47M | 394.93M |
| Selling & admin expenses | 43.34M | 57.93M | 62.34M | 110.82M | 123.06M | 144.50M | 155.78M | 165.41M |
| Research & development | 106.05M | 131.10M | 101.95M | 100.25M | 101.92M | 163.55M | 222.15M | 274.87M |
| Operating profit | -119.37M | -155.38M | -121.69M | -174.59M | -51.71M | -59.65M | -70.46M | -45.35M |
| Pretax profit | -111.89M | -165.45M | -119.06M | -179.88M | -40.88M | -60.89M | -52.94M | -19.10M |
| Tax | -21.00M | -29.18M | -18.08M | 150.00K | 11.66M | -5.60M | -1.85M | 16.41M |
| Net profit | -90.89M | -136.27M | -100.98M | -180.03M | -52.54M | -55.29M | -51.09M | -35.51M |
| Basic EPS | 0 | 0 | -3 | -4 | -1 | -1 | -1 | -1 |
| Diluted EPS | 0.00 | 0.00 | -3.18 | -4.24 | -1.15 | -1.13 | -1.02 | -0.71 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 93.88M | 97.96M | 103.69M | 104.48M | 106.68M | 115.93M |
| Gross profit | 93.05M | 96.92M | 103.18M | 101.78M | 106.24M | 114.84M |
| Selling & admin expenses | 40.20M | 42.79M | 39.78M | 42.65M | 37.85M | 43.89M |
| Research & development | 56.47M | 69.01M | 70.57M | 78.82M | 61.11M | 73.95M |
| Operating profit | -3.62M | -14.88M | -7.17M | -19.69M | 7.28M | -3.00M |
| Pretax profit | 6.08M | -9.69M | 304.00K | -15.79M | 13.27M | -514.00K |
| Tax | 1.06M | 606.00K | 481.00K | 14.27M | 301.00K | 294.00K |
| Net profit | 5.02M | -10.30M | -177.00K | -30.06M | 12.97M | -808.00K |
| Basic EPS | 0 | 0 | 0 | -1 | 0 | 0 |
| Diluted EPS | 0.10 | -0.20 | 0.00 | -0.60 | 0.25 | -0.02 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 217.21M | 162.95M | 208.42M | 354.58M | 473.98M | 528.82M | 929.86M | 996.74M |
| Cash & ST investments | 157.83M | 96.98M | 176.78M | 321.06M | 402.47M | 442.63M | 820.38M | 864.15M |
| Inventory | -- | -- | -- | 0 | 692.00K | 4.50M | 5.45M | 6.74M |
| Total assets | 248.42M | 243.42M | 268.74M | 407.28M | 526.76M | 597.00M | 1.01B | 1.07B |
| Total current liabilities | 62.95M | 110.81M | 74.95M | 82.57M | 100.84M | 139.02M | 212.18M | 246.70M |
| Short-term debt | -- | 27.68M | 2.78M | 1.69M | 1.88M | 1.39M | 1.55M | 2.01M |
| Long-term debt | 23.95M | -- | 49.95M | 50.24M | 47.81M | 48.01M | 391.01M | 393.13M |
| Total liabilities | 176,625,469.50 | 224,049,404.73 | 193,313,981.22 | 175,757,821.15 | 187,859,000.00 | 228,158,000.00 | 648,790,000.00 | 686,236,000.00 |
| Total equity | 71.80M | 19.37M | 75.43M | 231.53M | 338.90M | 368.84M | 360.72M | 381.03M |
| Retained earnings | -222.28M | -365.95M | -476.81M | -649.70M | -689.39M | -744.67M | -795.76M | -831.28M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 948.63M | 1.00B | 1.02B | 996.74M | 1.00B | 1.05B |
| Cash & ST investments | 837.03M | 882.81M | 892.35M | 864.15M | 844.90M | 880.21M |
| Inventory | 6.80M | 5.46M | 5.66M | 6.74M | 8.25M | 7.79M |
| Total assets | 1.03B | 1.08B | 1.10B | 1.07B | 1.07B | 1.12B |
| Total current liabilities | 149.16M | 170.08M | 170.35M | 246.70M | 240.11M | 235.20M |
| Short-term debt | 1.72M | 1.84M | 1.88M | 2.01M | 2.00M | 1.91M |
| Long-term debt | 391.53M | 392.06M | 392.59M | 393.13M | 393.66M | 394.21M |
| Total liabilities | 649,529,000.00 | 693,906,000.00 | 705,936,000.00 | 686,236,000.00 | 678,422,000.00 | 699,624,000.00 |
| Total equity | 378.48M | 388.48M | 396.56M | 381.03M | 393.67M | 419.80M |
| Retained earnings | -790.74M | -801.04M | -801.22M | -831.28M | -818.30M | -819.11M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -21.10M | -134.92M | -83.47M | -143.11M | -49.21M | 2.94M | 26.06M | -10.71M |
| Depreciation & amortization | 8.51M | 12.08M | 12.23M | 7.59M | 5.34M | 4.09M | 4.20M | 3.27M |
| Free cash flow | -25.58M | -140.53M | -87.66M | -144.49M | -51.41M | -2.49M | 20.89M | -15.05M |
| Dividends paid | 0 | 0 | 0 | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 78.50M | 113.41M | 286.89M | 139.52M | 0 | 0 | 0 |
| Ending cash balance | 157.83M | 96.98M | 176.78M | 321.08M | 402.47M | 442.63M | 455.73M | 467.71M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 435.00K | 25.96M | -4.46M | -32.66M | -13.78M | 15.93M |
| Depreciation & amortization | 854.00K | 780.00K | 798.00K | 834.00K | 948.00K | 1.03M |
| Free cash flow | 137.00K | 25.55M | -5.20M | -35.54M | -15.56M | 15.14M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 476.85M | 487.93M | 498.41M | 467.71M | 452.68M | 484.92M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -126.60 | -298.96 | -213.04 | -115.66 | -17.54 | -15.66 | -14.00 | -9.58 |
| ROA %i | -36.59 | -55.41 | -39.43 | -52.52 | -10.68 | -9.84 | -6.36 | -3.42 |
| ROIC %i | -94.90 | -121.15 | -75.61 | -70.91 | -12.54 | -15.32 | -9.25 | -4.83 |
| 5-year avg ROE %i | -- | -- | -- | -- | -154.86 | -132.67 | -75.68 | -34.99 |
| EBIT margin %i | -369.22 | -476.81 | -279.77 | -509.48 | -26.33 | -22.35 | -10.99 | -1.73 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | 6.73 | -- |
| Current ratioi | 3.45 | 1.47 | 2.78 | 4.29 | 4.70 | 3.80 | 4.38 | 4.04 |
| Quick ratioi | 3.44 | 1.47 | 2.78 | 4.29 | 4.56 | 3.63 | 4.26 | 3.91 |
| Debt / assetsi | 9.64 | 32.00 | 32.40 | 21.15 | 15.46 | 14.24 | 42.86 | 40.92 |
| LT debt / equityi | 33.36 | 259.29 | 111.74 | 36.48 | 23.48 | 22.67 | 119.53 | 114.08 |
| Interest coveragei | -103.72 | -32.24 | -27.10 | -23.24 | -6.01 | -10.81 | -1.81 | -0.57 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 6.72 | 73.03 | 82.49 | 104.10 | 31.89 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -5.86 | -5.43 | -7.55 | -9.58 | -7.14 | -4.47 |
| ROA %i | -2.14 | -1.93 | -2.67 | -3.42 | -2.63 | -1.64 |
| ROIC %i | -2.97 | -2.71 | -3.63 | -4.83 | -3.62 | -2.36 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -1.24 | -1.45 | -3.21 | -1.73 | 0.07 | 2.19 |
| FCF / sales %i | 7.81 | 7.99 | 0.78 | -- | -- | -- |
| Current ratioi | 6.36 | 5.89 | 6.00 | 4.04 | 4.18 | 4.47 |
| Quick ratioi | 6.03 | 5.60 | 5.68 | 3.91 | 3.86 | 4.15 |
| Debt / assetsi | 42.22 | 40.32 | 39.53 | 40.92 | 40.64 | 38.86 |
| LT debt / equityi | 114.21 | 111.88 | 109.44 | 114.08 | 110.16 | 103.16 |
| Interest coveragei | -0.22 | -0.30 | -0.77 | -0.57 | 0.02 | 0.78 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Immunotherapies100.00%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.